title: Brentuximab Vedotin Therapy for Cutaneous Lesions in T-Prolymphocytic Leukemia: A Case Report.
abstract: We present an 88-year-old male with simultaneous T-cell prolymphocytic leukemia and stable smoldering myeloma with excellent initial response to three months of alemtuzumab. The patient relapsed at twelve months with severe cutaneous disease. Biopsy of a representative plaque demonstrated CD30 positivity in rare malignant lymphocytes. The patient demonstrated no response to reintroduction with a full course of alemtuzumab. He was therefore treated with brentuximab vedotin, resulting in partial remission of skin involvement that persisted for three months.
authors.affiliation: Drexel University College of Medicine, Philadelphia , Abington, PA, USA.
authors.forename: Jordan
authors.initials: J
authors.lastname: Senchak
authors.affiliation: Department of Hematology/Oncology, Abington Memorial Hospital , Abington, PA, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Pickens
keywords: T-prolymphocytic leukemia; alemtuzumab; brentixumab vedotin